Section Arrow
Quote
SRRK.NASDAQ
- Scholar Rock Holding Corp
Quotes are at least 15-min delayed:2026/07/17 03:39 EDT
Regular Hours
Last
 51.73
-2.31 (-4.27%)
Day High 
53.94 
Prev. Close
54.04 
1-M High
58.49 
Volume 
1.05M 
Bid
--
Ask
--
Day Low
50.825 
Open
53.755 
1-M Low
44.45 
Market Cap 
6.48B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 55.28 
20-SMA 53.2 
50-SMA 49.66 
52-W High 58.49 
52-W Low 27.07 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.45/-2.20
Enterprise Value
6.58B
Balance Sheet
Book Value Per Share
2.30
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1477+0.0332+29.00%-- 
ATAIAtaiBeckley Inc7.15+1.79+33.40%-- 
KAPAKairos Pharma Ltd.0.3399+0.0219+6.89%-- 
RXRXRecursion Pharmaceuticals3.02-0.29-8.76%-- 
IOVAIovance Biotherapeutics4.66-0.08-1.69%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.